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To the Editor: In recent years, various techniques to identify
high-risk atherosclerotic plaques have been introduced (1).
But development of therapies targeted at plaque vulnerability is
lagging behind. The theranostic approach, in which the same
molecule is used for diagnosis and subsequent therapy, is increas-
ingly being used in oncology. In neuroendocrine tumors, e.g.,
expression of somatostatin receptor subtype-2 (SSTR-2) is visual-
ized by 68Gallium-[1,4,7,10-tetraazacyclododecane-N,N0,N,N0-
tetraacetic acid]-D-Phe1,Tyr3-octreotate (68Ga-DOTATATE)
positron emission tomography/computed tomography (PET/CT),
and often followed by peptide receptor radionuclide therapy (PRRT)
with DOTATATE bound to the beta-emitter 177Lutetium (2).
SSTR-2 is also overexpressed on activated macrophages (3). 68Ga-
DOTATATE uptake has been reported in coronaries (4) and large
arteries (5), where it correlates with established risk markers. We
speculated that SSTR-2 may provide a theranostic opportunity to
characterize and modulate atherosclerotic plaque biology, and we
sought to collect initial evidence from a retrospective analysis of
oncology patients.
Of 165 consecutive patients undergoing PRRT, we identiﬁed
11 patients (9 male subjects, 2 female subjects; mean age 60  13
years) who had 3 successive 68Ga-DOTATATE PET/CT scans
and received their ﬁrst PRRT according to standard protocol (2)
after disease progression was conﬁrmed by the second scan. The
median number of days between scans 1 and 2 was 347 (range 99 to
945); between scan 2 and PRRT, it was 28 (range 14 to 89); and
between PRRT and scan 3, it was 105 (range 76 to 131). Exclusion
criteria included medical history of vasculitis, rheumatoid disease,
cardiovascular events within 5 years before scan 1, or systemic
chemotherapy from 4 weeks before scan 1 until end of imaging. Four
patients took vasoactive medication (statins, n ¼ 1; antihypertensive
agents, n ¼ 3), the dosages of which remained stable. Standard
whole-body images were acquired 30  10 min after intravenous
injection of 73  13 MBq 68Ga-DOTATATE, using a Biograph
Duo PET/CT (Siemens Medical Solutions, Erlangen, Germany).
The mean effective dose per PET scan was 1.88 mSv (6). Mean
therapeutic activity of 177Lu-DOTATATE was 7.5  0.3 GBq.
Scans 1 and 2 were used to estimate whether vessel wall uptake was
stable over time. Scan 3 was used to identify PRRT-related changes.
Focal vessel wall DOTATATE uptake was measured in 6 arterial
segments (carotids; aortic arch; ascending, descending, and ab-
dominal aorta; iliac arteries). Target-to-background ratio was de-
termined by dividing the maximal standardized uptake value of
a vessel focus by the mean standardized uptake value of 5 regions
of interest in the superior vena cava, which represented the mean
blood pool uptake. Overall vessel uptake was determined as the sum
of target-to-background-ratios in all vascular segments of each scan.
CT was used to detect calciﬁed plaque, with a cutoff of 130 Houns-
ﬁeld units. Continuous variables, expressed as mean  SD, were
compared by using analysis of variance and post-hoc Bonferroni-
corrected t tests. The relationship between variables was determinedby using Pearson’s correlation coefﬁcient. The Mann-Whitney U
test was used to compare subgroups with and without hypercholes-
terolemia or calciﬁcation. A p value<0.05 was considered signiﬁcant.
Focal 68Ga-DOTATATE vessel wall uptake was detectable in all
patients (Fig. 1A). At baseline, overall vessel uptake correlated
signiﬁcantly with cardiovascular risk factors (patient age, r ¼ 0.76,
p< 0.01 [Fig. 1B]; number of calciﬁed plaques, r¼ 0.84, p< 0.001).
In the presence of hypercholesterolemia, overall vessel uptake was
signiﬁcantly higher (71.6  3.9 with vs. 35.0  18.3 without;
p ¼ 0.04). No signiﬁcant difference in overall vessel uptake was
found between scans 1 and 2 (42  23 vs. 41  26; p ¼ 0.8). After
PRRT, however, a signiﬁcant reduction was observed in scan 3 (30
19; p ¼ 0.003 and p ¼ 0.012 vs. scans 1 and 2) (Figs. 1C and 1D).
Of note, the number of calciﬁed plaques remained stable over time.
When analyzed on a lesion-by-lesion basis, PRRT-related reduction
of DOTATATE uptake was more pronounced in noncalciﬁed ver-
sus calciﬁed active plaque (9.6 7.1 vs. 2.1 3.2; p¼ 0.047).Analysis
on a segment-by-segment basis found that changes in the 6 different
vascular beds mostly paralleled the overall vessel uptake change.
In summary, our results show the feasibility of 68Ga-
DOTATATE PET/CT for characterizing biological activity of
atherosclerotic plaque via SSTR-2 expression. Vessel wall lesions were
observed reproducibly without treatment over a longer period of time
that was driven by clinical criteria in this retrospective analysis.
Although histopathologic proof of plaque vulnerability and data on
short-term reproducibility are still missing and should be the subject
of subsequent work, our initial observations in oncology patients
suggest that DOTATATE-based, SSTR-2–targeted PRRT results
in a reduction in atherosclerotic plaque activity. Other limitations of
this work, such as retrospective design, small sample size, and
concomitant oncologic disease, need to be considered. Nevertheless,
our results may serve as a stimulus for further prospective exploration
of radionuclide-based antiatherosclerotic molecular interventions.
Ultimately, such therapies (which may also be catheter-based and
targeted to speciﬁc vascular regions) might be used to lower the
degree of inﬂammation in high-risk atherosclerosis.Imke Schatka, MDy
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Figure 1 Somatostatin Receptor Subtype-2–based PET/CT Imaging of Atherosclerosis
(A) Whole-body imaging by 68Gallium-[1,4,7,10-tetraazacyclododecane-N,N0,N,N0 -tetraacetic acid]-D-Phe1,Tyr3-octreotate (68Ga-DOTATATE) positron emission tomography/
computed tomography (PET/CT) of a patient with metastatic neuroendocrine tumor. Maximum intensity projection (left) shows DOTATATE biodistribution. Transaxial
fused PET/CT scan (right; full image and magniﬁcation) at the location of the lower kidneys shows plaque, with focal uptake in the abdominal aorta, partially calciﬁed on the
CT scan. (B) Regression plot for DOTATATE overall vessel uptake (OVU) index and patient age at the time of scan 1. (C) Group results of OVU at the time of 3 scans (red
bar indicates timing of peptide receptor radionuclide therapy [PRRT]). (D) Representative example of a calciﬁed and initially DOTATATE-avid aortic arch plaque showing stable
target-to-background ratio (TBR) between scans 1 and 2. It declined after PRRT.
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2013;54:855–60.Letters to the EditorDiagnosis of “Paradoxical” Low-
Gradient Aortic Stenosis PatientsThe report by Lauten et al. (1) investigates a very important clinical
presentationd“paradoxical” low-gradient aortic stenosis (PLG AS).
This is a diagnostic challenge, and their work deﬁnitely improves our
understanding of this problem. However, we found multiple
inconsistencies and unclear explanations that we wish to highlight.
First, the authors compared echocardiographic and catheteri-
zation data in PLG AS to evaluate errors and bias of echocar-
diography measurements. Unfortunately, this inherently assumes
that catheterization measurements represent a veritable “gold-
standard” measurement. Cardiac catheterization has inherent
errors and uncertainties, including uncertainty in measuring stroke
volume, errors in pressure measurements, and assumption of
identical hemodynamic conditions between catheterization and
echocardiography. A bench-top in vitro study might provide
